Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
female (10) 10
male (10) 10
aged (8) 8
life sciences & biomedicine (8) 8
middle aged (8) 8
science & technology (8) 8
abridged index medicus (6) 6
cardiovascular disease (6) 6
cardiovascular diseases (6) 6
double-blind method (6) 6
myocardial infarction (6) 6
stroke (6) 6
cerebral infarction (5) 5
diabetes (5) 5
health risk assessment (5) 5
heart attacks (5) 5
acute coronary syndromes (4) 4
angina pectoris (4) 4
cardiac & cardiovascular systems (4) 4
cardiovascular diseases - prevention & control (4) 4
cardiovascular system & cardiology (4) 4
cholesterol (4) 4
coronary artery disease (4) 4
general & internal medicine (4) 4
health risks (4) 4
heart diseases (4) 4
medicine, general & internal (4) 4
randomization (4) 4
risk factors (4) 4
adult (3) 3
alirocumab (3) 3
angina (3) 3
disease control (3) 3
evidence-based medicine (3) 3
ischemia (3) 3
lipids (3) 3
lipoproteins (3) 3
mortality (3) 3
patients (3) 3
prospective studies (3) 3
statins (3) 3
agonists (2) 2
argentina - epidemiology (2) 2
blood pressure (2) 2
cardiovascular diseases - epidemiology (2) 2
cardiovascular diseases - mortality (2) 2
clinical trials (2) 2
confidence intervals (2) 2
coronary artery (2) 2
diabetes mellitus (2) 2
diabetes mellitus, type 2 - drug therapy (2) 2
drug dosages (2) 2
drug therapy, combination (2) 2
eye diseases (2) 2
follow-up studies (2) 2
genetic structures (2) 2
glucagon (2) 2
glucagon-like peptide 1 (2) 2
glucagon-like peptides - analogs & derivatives (2) 2
glucagon-like peptides - therapeutic use (2) 2
hemoglobin (2) 2
hypoglycemic agents - therapeutic use (2) 2
immunoglobulin fc fragments - therapeutic use (2) 2
incidence (2) 2
insulin resistance (2) 2
kexin (2) 2
medicin och hälsovetenskap (2) 2
myocardial infarction - prevention & control (2) 2
ophthalmology (2) 2
peptides (2) 2
recombinant fusion proteins - therapeutic use (2) 2
risk analysis (2) 2
sense organs (2) 2
stroke - prevention & control (2) 2
subtilisin (2) 2
therapy (2) 2
[sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
[sdv.mhep]life sciences [q-bio]/human health and pathology (1) 1
[sdv]life sciences [q-bio] (1) 1
acute coronary syndrome (1) 1
acute coronary syndrome - blood (1) 1
acute coronary syndrome - complications (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndrome - surgery (1) 1
adaptation, physiological - physiology (1) 1
administration & dosage (1) 1
administration, oral (1) 1
adverse effects (1) 1
albuminuria - prevention & control (1) 1
alirocumab • prevention • mi types • mortality (1) 1
aliskiren (1) 1
amides - administration & dosage (1) 1
analysis (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - therapeutic use (1) 1
anticoagulants (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
by Schwartz, Gregory G and Steg, P. Gabriel and Szarek, Michael and Bhatt, Deepak L and Bittner, Vera A and Diaz, Rafael and Edelberg, Jay M and Goodman, Shaun G and Hanotin, Corinne and Harrington, Robert A and Jukema, J. Wouter and Lecorps, Guillaume and Mahaffey, Kenneth W and Moryusef, Angèle and Pordy, Robert and Quintero, Kirby and Roe, Matthew T and Sasiela, William J and Tamby, Jean-François and Tricoci, Pierluigi and White, Harvey D and Zeiher, Andreas M and ODYSSEY OUTCOMES Comm Inv and ODYSSEY OUTCOMES Committees and Investigators
The New England journal of medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
by Bittner, Vera A and Szarek, Michael and Aylward, Philip E and Bhatt, Deepak L and Diaz, Rafael and Edelberg, Jay M and Fras, Zlatko and Goodman, Shaun G and Halvorsen, Sigrun and Hanotin, Corinne and Harrington, Robert A and Jukema, J. Wouter and Loizeau, Virginie and Moriarty, Patrick M and Moryusef, Angèle and Pordy, Robert and Roe, Matthew T and Sinnaeve, Peter and Tsimikas, Sotirios and Vogel, Robert and White, Harvey D and Zahger, Doron and Zeiher, Andreas M and Steg, Ph. Gabriel and Schwartz, Gregory G and ODYSSEY OUTCOMES Committees and Investigators and ODYSSEY OUTCOMES Comm
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2020, Volume 75, Issue 2, pp. 133 - 144
proprotein convertase subtilisin/kexin type 9 inhibition | alirocumab | low-density lipoprotein cholesterol | acute coronary syndromes | major adverse cardiovascular events | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Myocardial infarction | Lipoproteins (low density) | Heart attacks | Risk | Cardiovascular disease | Angina | Confidence intervals | Variables | Reduction | Demographics | Randomization | Ischemia | Heart diseases | Statins | Cerebral infarction | Stroke | Health risks | Subtilisin | Apolipoproteins | Angina pectoris | Patients | Coronary artery disease | Cholesterol | Lipoproteins | Kexin | Diabetes | Acute coronary syndromes | Cardiovascular diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
by White, Harvey and Steg, Philippe Gabriel and Szarek, M and Bhatt, Deepak and Bittner, V.A and Díaz, Rafael and Edelberg, J.M and Erglis, Anejs and Goodman, S.G and Hanotin, C and Harrington, Robert Alex and Jukeme, J. Wouter and Lopes, R.D and Mahaffey, Kenneth and Moryusef, A and Pordy, R and Roe, Matthew and Sritara, P and Tricoci, P and Simoons, Maarten and Sijbrands, Eric and Zeiher, Aneas and Schwartz, Gregory and ODYSSEY OUTCOMES Investigators
European heart journal, ISSN 0195-668X, 09/2019, Volume 40, Issue 33, pp. 2801 - 2809
Alirocumab • Prevention • MI types • Mortality | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Index Medicus | Prevention | MI types | Alirocumab | Mortality | Fast Track Clinical Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
by Aylward, Philip E and Diaz, Rafael and Edelberg, Jay M and Harrington, Robert A and Jukema, J. Wouter and Pordy, Robert and Zeiher, Andreas M and Schwartz, Gregory G and Sinnaeve, Peter and Dilic, Mirza and Lopes, Renato D and Gotcheva, Nina N and Yong, Huo and Pecin, Ivan and Viigimaa, Margus and Nieminen, Markku S and Chumburidze, Vakhtang and Montenegro Valdovinos, Pablo Carlos and Valgimigli, Marco and Laucevicius, Aleksandras and Kedev, Sasko and Halvorsen, Sigrun and Chua, Terrance and Murin, Jan and Dalby, Anthony J and de Silva, H. Asita and Chiang, Chern-En and Ray, Kausik K and Vogel, Robert and Rouleau, Jean-Lucien and Meloni, Chiara and Sijbrands, Eric J. G and Armaganijan, Luciana and Clifton, Shaun and DeVore, Adam D and Dickey, Sheila and Eppinger, Arleen and Hess, Connie Ng and Kolls, Bradley J and Lopes, Renato D and Mehta, Rajendra H and Moreira, Humberto Graner and Pereira, Sabrina Bernardez and Puymirat, Etienne and Shah, Bimal R and Wilson, Matthew D and Alvarisqueta, Andres F and Bordonava, Anselmo P and Alves De Lima, Alberto E and Duronto, Ernesto A and Montana, Oscar R and Gomez Vilamajo, Oscar A and Lorenzatti, Alberto J and Paterlini, Gustavo A and Mackinnon, Ignacio J and Amuchastegui, Marcos and Jure, Horacio O and Bono, Julio O. E and Novoa, Federico and Dran, Ricardo D and Carnero, Gabriela S and Medrano Allende, Juan C and Nani, Sebastian and Berli, Mario A and Garcia Duran, Ruben O and Luquez, Hugo A and Giordano, Jorge A and Saavedra, Silvia S and Collins, Nicholas and Arstall, Margaret A and Rogers, James F and Flores, Romulo E. Oqueli and Raffel, Owen and Lehman, Sam J and Starmer, Gregory and Huber, Kurt and Wollaert, Bart and Dujardin, Karl and Roosen, John and Barbato, Emanuele and Cools, Frank and Durak-Nalbantic, Azra and Vulic, Dusko and Muslibegovic, Adis and Sousa, Luciano and Giorgeto, Flavio E and Rossi, Paulo R. F and Kalil, Renato and Kormann, Adrian and Pimentel Filho, Pedro and Soggia, Ana Priscila and de Santos, Mayler O. N and Vidotti, Maria H and Leaes, Paulo E and Kaiser, Sergio and Precoma, Dalton B and Saporito, Wladimir and Marin Neto, Jose A and Feitosa, Gilson S and Ritt, Luiz Eduardo F and ... and ODYSSEY OUTCOMES Comm Investigator and ODYSSEY OUTCOMES Committees and Investigators
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2019, Volume 74, Issue 9, pp. 1177 - 1186
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Postoperative Complications - prevention & control | Male | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Acute Coronary Syndrome - surgery | Coronary Artery Bypass | Female | Aged | Drug Therapy, Combination | Myocardial infarction | Therapy | Heart attacks | Cardiovascular disease | Angina | Confidence intervals | Randomization | Ischemia | Surgery | Heart diseases | Statins | Cerebral infarction | Evaluation | Stroke | Mortality | Coronary artery | Health risks | Angina pectoris | Patients | Coronary artery disease | Lipoproteins | Death | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment
Journal Article
Details down arrow
5. Full Text Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: Insights from the ASTRONAUT trial
by Maggioni, Aldo P and Greene, Stephen J and Fonarow, Gregg C and Böhm, Michael and Zannad, Faiez and Solomon, Scott D and Lewis, Eldrin F and Baschiera, Fabio and Hua, Tsushung A and Gimpelewicz, Claudio R and Lesogor, Anastasia and Gheorghiade, Mihai and ASTRONAUT Investigators and ASTRONAUT Investigators and Coordinators and for the ASTRONAUT Investigators and Coordinators
European heart journal, ISSN 0195-668X, 10/2013, Volume 34, Issue 40, pp. 3117 - 3127
Aliskiren | Diabetes | Post-discharge | Outcomes | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Prospective Studies | Diabetic Cardiomyopathies - drug therapy | Double-Blind Method | Administration, Oral | Diabetic Cardiomyopathies - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Fumarates - administration & dosage | Male | Treatment Outcome | Death, Sudden, Cardiac - etiology | Heart Failure - drug therapy | Cardiotonic Agents - administration & dosage | Renin - antagonists & inhibitors | Female | Amides - administration & dosage | Heart Failure - mortality | Index Medicus | Esc Fasttrack
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Vitrectomy with complete posterior hyaloid removal for ischemic central retinal vein occlusion: Series of cases
by Leizaola-Fernández, Carlos and Suárez-Tatá, Luis and Quiroz-Mercado, Hugo and Colina-Luquez, Juner and Fromow-Guerra, J and Jiménez-Sierra, Juan M and Guerrero-Naranjo, Jose L and Morales-Cantón, Virgilio
BMC ophthalmology, ISSN 1471-2415, 05/2005, Volume 5, Issue 1, pp. 10 - 10
Electroretinography | Retinal Vein Occlusion - physiopathology | Prospective Studies | Follow-Up Studies | Tomography, Optical Coherence | Humans | Middle Aged | Intraocular Pressure - physiology | Male | Ischemia - physiopathology | Basement Membrane - surgery | Retinal Vessels | Retinal Vein Occlusion - surgery | Female | Ischemia - surgery | Vitrectomy | Aged | Visual Acuity - physiology | Fluorescein Angiography | Vitreous Body - surgery | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]
by Agurto-Rivera, Ricardo and Diaz-Rubio, Jose and Torres-Bernal, Luis and Macky, Tamer A and Colina-Luquez, Juner and Papa-Oliva, Gabriela and Jager, Rama D and Martinez-Jardon, Susana and Fromow-Guerra, Jans and Quiroz-Mercado, Hugo
BMC ophthalmology, ISSN 1471-2415, 11/2005, Volume 5, Issue 1, pp. 27 - 27
Glucocorticoids - therapeutic use | Prospective Studies | Humans | Macular Degeneration - complications | Choroidal Neovascularization - therapy | Triamcinolone Acetonide - therapeutic use | Choroidal Neovascularization - etiology | Combined Modality Therapy | Visual Acuity | Pupil | Injections | Pilot Projects | Macular Degeneration - therapy | Vitreous Body | Aged | Hyperthermia, Induced - methods | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
by Dagenais, Gilles R and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Riesmeyer, Jeffrey S and Riddle, Matthew C and Rydén, Lars and Dyal, Leanne and Chung, Namsik and Conget, Ignacio and Cushman, William C and Hancu, Nicolae and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Lanas, Fernando and Cardona Munoz, Ernesto German and Pogosova, Nana and Shaw, Jonathan E and Temelkova-Kurktschiev, Theodora and Alebuena, Andrea and Almagro, Sandra and Bustamante Labarta, Miguel and Bustos, Betina and Cantero, Maria and Costamagna, Osvaldo and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dominguez, Andrea and Fernandez, Alberto and Gallardo, Karina Beatriz and Garcia Duran, Ruben and Gerbaudo, Claudio and Giotto, Ana Paula and Godoy Bolzán, Pedro and Hermida, Sonia and Hrabar, Adrian and Ingaramo, Adrián and Krynski, Mario and Lagrutta, Mariana and Lanchiotti, Paulina and Matias, Re and Pruyas, Lorena and Ricotti, Carola and Rodriguez, Carolina and Romero Vidomlansky, Mariano and Ronderos, Ricardo and Sadowski, Ana Laura and Sala, Jorgelina and Sernia, Virginia and Sicer, Maximiliano and Smith, Tomas and Stival, Jorge and Vallejos, Julio and Virgillito, Luciana and Vogel, Daniel and Zucchiatti, Noemi and Colquhoun, David and Davis, Timothy and Fourlanos, Spiros and Jeffries, William and Lo, Clement and Makepeace, Ashley and Marope, Dolly and Pillai, Satish and Reutens, Anne and Sheikh, Abdul and Smith, Greg and Castro, Denise Ludovico da Costa de and Correa da Cruz, Ivan and Costa, Midiã and Cunha, Sidney and de Carvalho Camara Bona, Renata and Eliaschewitz, Freddy and França, Cesar and Genestreti, Paulo Roberto and Grossman, Michele Elka and Hernandes, Mauro and Horta, Ana and Manenti, Euler Roberto and Marques, Mariana and Mothé, Flávia and Moura, Philip and Moura Jorge, José Carlos and Nakashima, Carlos and Nakazone, Marcelo and Napoli, Thiago and Pizzato, Patricia and Reis, Heleno and Ribas Fortes, Jose and Rossi dos Santos, Fabio and Santos, Thiago and Teireira, M and Dimitrov, Georgi and Dimova, Kameliya and Dragoychev, Tsvetan and Grigorova, Valentina and Ivanov, Ivaylo and Kurktschiev, Dimo and ... and REWIND Investigators
The Lancet (British edition), ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Stroke - prevention & control | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Cardiovascular Diseases - mortality | Female | Aged | Glucagon-Like Peptides - therapeutic use | Immunoglobulin Fc Fragments - therapeutic use | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptides - analogs & derivatives | Diabetes Mellitus, Type 2 - complications | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Evidence-based medicine | Risk factors | Incidence | Randomization | Older people | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
by Connolly, Stuart J and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Hori, Masatsugu and Cook Bruns, Nancy and Anand, Sonia S and Varigos, John D and Fox, Keith A A and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and GARRIDO, MARCELO and INGARAMO, ADRIAN and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and GUZMAN, LUIS and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and DUTRA, OSCAR and BRAILE, MARIA and IZUKAWA, NILO and NICOLAU, JOSE CARLOS and TANAJURA, LUIZ FERNANDO and MINELLI, CESAR and OLIVEIRA, LIVIA and DE CARVALHO CANTARELLI, MARCELO JOSE and TYTUS, RICHARD and PANDEY, SHEKHAR and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and SAUNDERS, KEVIN and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and AL-QOOFI, FAISAL and BROWN, CRAIG and RICCI, JOSEPH A and GLANZ, ANTHONY and NOISEUX, NICOLAS and ... and COMPASS investigators and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Evidence-based medicine | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Drug | drug therapy | chemically induced | prevention & control | Coronary Artery Disease | Clinical Medicine | Myocardial Infarction | Platelet Aggregation Inhibitors | adverse effects | mortality | Dose-Response Relationship | therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights